DV
Dividend Vision

NRIX — Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. (NRIX)

Total return is 42.3% over the past 6.1 years, 120.4 points behind SPY at 162.7%. Its deepest 1-year drawdown was 32.8%.

NRIX is a single-stock equity holding that trades as a public company rather than functioning as a traditional ETF with a diversified portfolio. The security does not currently distribute dividends and therefore carries no yield profile or regular distribution schedule. This holding may appeal primarily to growth-oriented investors seeking exposure to the biotechnology sector rather than income-focused investors.

NRIX key facts

Asset type
Stock
Asset class
Equity
Inception date
07/24/2020
Distribution frequency
None
Last close
$27.05
Market cap
$2,807,294,464
Average volume
738504.0
Beta
1.794
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.44